Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

InnoCare In-Licenses CD19 Lymphoma Therapy in $117.5 Million Deal

publication date: Aug 17, 2021

Beijing InnoCare in-licensed greater China rights to a CD19 targeting mAb from Delaware-based Incyte in a $117.5 million agreement. Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. It mediates B-cell lysis through apoptosis and an immune effector. InnoCare will pay Incyte $35 million upfront and up to an additional $82.5 million in milestones, plus tiered royalties. In the EU, tafasitamab is conditionally approved for adult patients with diffuse large B-cell lymphoma. More details....

Stock Symbols: (HK: 09969) (NSDQ: INCY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.